cobas EGFR Mutation Test, v2.0
Roche · Decision date Dec 31, 2025
What did the FDA decide?
FDA records P120019/S042 as a supplement to PMA P120019, with the supplement type “30-Day Notice”. The recorded decision is OK30 (30-day notice), dated Dec 31, 2025.
FDA approval order statement
changes to QC testing of filters used in reagent manufacturing
- Regulatory pathway
- PMA supplement
- Supplement type
- 30-Day Notice
- Clinical specialty
- Pathology
- Decision date
- Dec 31, 2025
- FDA change category
- Process Change - Manufacturer/Sterilizer/Packager/Supplier
Regulatory record facts
- Identifier
- P120019/S042
- Regulatory pathway
- PMA supplement
- Applicant
- Roche
- Product code
- OWD
- Decision code
- OK30
- Decision date
- Dec 31, 2025
- Source update
- Nov 9, 2026
- Original record
- Open FDA source record
About this medical device
FDA device category: Somatic gene mutation detection system.
For the original device and its historical approval scope, see PMA P120019. Subsequent supplements may change the device or its indications.
FDA decision timeline
P120019 · Original PMA
COBAS EGFR MUTATION TEST
P120019/S042 received
Application receipt date recorded by FDA.
P120019/S042 · FDA decision
30-Day Notice
P120019/S043 · Related supplement
cobas EGFR Mutation Test, v2.0
P120019/S044 · Related supplement
cobas EGFR Mutation Test, v2.0
P120019/S045 · Related supplement
Roche cobas EGFR Mutation Test, v2.0
Timeline entries are records held by MedtechLedger for P120019. View FDA’s full supplement list.
Related devices and submissions
Same PMA: P120019
| Product / regulatory record | Company | Pathway | Decision date | Source |
|---|---|---|---|---|
COBAS EGFR MUTATION TESTP120019 | Roche | PMA approval | May 14, 2013 | FDA |
cobas EGFR Mutation Test, v2.0P120019/S043 | Roche | PMA supplement | Mar 17, 2026 | FDA |
cobas EGFR Mutation Test, v2.0P120019/S044 | Roche | PMA supplement | Oct 27, 2026 | FDA |
Roche cobas EGFR Mutation Test, v2.0P120019/S045 | Roche | PMA supplement | Nov 4, 2026 | FDA |
Explore the linked device profile
Other records with product code OWD
| Product / regulatory record | Company | Pathway | Decision date | Source |
|---|---|---|---|---|
Roche cobas BRAF V600 Mutation TestP110020/S046 | Roche Molecular Systems, Inc. | PMA supplement | Nov 4, 2026 | FDA |
Roche cobas KRAS Mutation TestP140023/S034 | Roche Molecular Systems, Inc. | PMA supplement | Nov 4, 2026 | FDA |
cobas BRAF V600 Mutation TestP110020/S045 | Roche Molecular Systems, Inc. | PMA supplement | Oct 27, 2026 | FDA |
cobas KRAS Mutation TestP140023/S033 | Roche Molecular Systems, Inc. | PMA supplement | Oct 27, 2026 | FDA |
cobas EZH2 Mutation TestP200014/S012 | Roche Molecular System, Inc. | PMA supplement | Oct 27, 2026 | FDA |
A shared product code identifies a classification relationship; it does not establish clinical equivalence.
Regulatory context
A PMA supplement records a change to a device with an existing premarket approval. The supplement’s approval applies to the change described in that submission.
Read our guide to FDA clearance and approval · FDA’s explanation of this pathway
Manufacturer intelligence
Roche
- Headquarters
- Not reported
- Brand website
- Not reported
- FDA applicant address
- 4300 Hacienda Dr., P.O. Box 9002, Peasanton, CA, 94588
Sources and methodology
- Original FDA record: P120019/S042
- openFDA source data · Source release Nov 9, 2026 · Retrieved Nov 21, 2026
FDA fields and approval-order wording are presented as source information. MedtechLedger explanations are identified separately and describe the scope of the recorded decision. Indications from an original PMA are historical unless confirmed against subsequent labeling and supplements.
How we use FDA records




